Immunotherapy alone for advanced lung cancer with high PD-L1
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether using immunotherapy drugs (pembrolizumab or cemiplimab) alone, without chemotherapy, can treat advanced lung cancer in people with high PD-L1 levels. It is for people who have not yet received any treatment for their advanced cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- This is your first treatment for advanced lung cancer that has spread.
- Your lung cancer has a high PD-L1 level (at least 50%).
- Your cancer does not have EGFR, ALK, or ROS1 gene changes.
- You have not had immunotherapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (cemiplimab) and chemotherapy for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. It looks at whether this treatment works better when certain immune cells in the blood are high.
This trial studies whether pembrolizumab combined with standard chemo can treat locally advanced, unresectable stage III lung cancer without giving radiation first. It is intended for people whose tumor has high PD-L1 (a marker linked to how well immunotherapy may work).
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a drug called pembrolizumab (Keytruda) in people with advanced non-small cell lung cancer who haven't received treatment for metastatic disease. Researchers will also study your T-cells (a type of immune cell) to see if they can predict how well the drug works.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Hear when a new Non Small Cell Lung Cancer (Squamous or Non Squamous) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.